Nrx pharmaceuticals reports first quarter 2023 financial results and provides business update

Enrollment continues in the phase 2b/3 clinical trial evaluating nrx-101 in suicidal treatment-resistant bipolar depression; data expected in 4q 2023 national educational campaign launched to further accelerate enrollment in breakthrough therapy designation meeting for nrx-101 in suicidal treatment-resistant bipolar depression with the u.s. fda planned for 2q 2023; on track to report topline clinical data in 4q 2023 ended quarter with $16.5 million in cash and cash equivalents management to host a conference call and webcast today at 8:30 a.m. et radnor, pa.
NRXP Ratings Summary
NRXP Quant Ranking